Operational Costs Compared: SG&A Analysis of Incyte Corporation and Perrigo Company plc

A Decade of SG&A: Incyte vs. Perrigo

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Incyte Corporation and Perrigo Company plc have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by an impressive 600%, reflecting its aggressive expansion and strategic investments. In contrast, Perrigo's expenses grew by approximately 89%, indicating a more stable operational approach.

Key Insights

• Incyte's Growth: Starting at just 16% of Perrigo's expenses in 2014, Incyte closed the gap significantly by 2023, reaching 91% of Perrigo's SG&A costs.
• Perrigo's Stability: Despite fluctuations, Perrigo maintained a consistent upward trend, peaking in 2023.

This analysis underscores the dynamic strategies of these pharmaceutical giants, offering a window into their operational priorities and market positioning.